Browsing ICR Divisions by author "Denis-Bacelar, Ana"
Now showing items 1-6 of 6
-
Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy.
Denis-Bacelar, AM; Chittenden, SJ; McCready, VR; Divoli, A; Dearnaley, DP; et al. (BRITISH INST RADIOLOGY, 2018-01-01)OBJECTIVE: The aim of this study was to calculate the range of absorbed doses that could potentially be delivered by a variety of radiopharmaceuticals and typical fixed administered activities used for bone pain palliation ... -
Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma.
George, SL; Falzone, N; Chittenden, S; Kirk, SJ; Lancaster, D; et al. (SPRINGER, 2013-10-01)OBJECTIVE: Iodine-131-labelled meta-iodobenzylguanidine (I-mIBG) therapy is an established treatment modality for relapsed/refractory neuroblastoma, most frequently administered according to fixed or weight-based criteria. ... -
Individualized I-131-mIBG therapy in the management of refractory and relapsed neuroblastoma
George, SL; Falzone, N; Chittenden, S; Kirk, SJ; Lancaster, D; et al. (2016-05-01) -
Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival.
Denis-Bacelar, AM; Chittenden, SJ; Dearnaley, DP; Divoli, A; O'Sullivan, JM; et al. (SPRINGER, 2017-04-01)PURPOSE: To investigate the role of patient-specific dosimetry as a predictive marker of survival and as a potential tool for individualised molecular radiotherapy treatment planning of bone metastases from castration-resistant ... -
Pre-clinical quantitative imaging and mouse-specific dosimetry for 111In-labelled radiotracers.
Denis-Bacelar, AM; Cronin, SE; Da Pieve, C; Paul, RL; Eccles, SA; et al. (SPRINGER HEIDELBERG, 2016-11-25)BACKGROUND: Accurate quantification in molecular imaging is essential to improve the assessment of novel drugs and compare the radiobiological effects of therapeutic agents prior to in-human studies. The aim of this study ... -
Reply to 'Single high dose versus repeated bone-targeted radionuclide therapy'.
Denis-Bacelar, AM; Chittenden, SJ; Dearnaley, DP; Divoli, A; O'Sullivan, JM; et al. (SPRINGER, 2018-03-01)